Cited by 306Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 164 of the 165 references it cites were found in a registry or an index.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality

Open access

Wadhera, Rishi K., Steen, Dylan L., Khan, Irfan, Giugliano, Robert P., Foody, JoAnne M.·2016·Journal of Clinical Lipidology

DOI 10.1016/j.jacl.2015.11.010

Open this paper in CoChat — free account

Abstract

Cardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximately 31.4% of deaths globally in 2012. It is estimated that, from 1980 to 2000, reduction in total cholesterol accounted for a 33% decrease in coronary heart disease (CHD) deaths in the United States. In other developed countries, similar decreases in CHD deaths (ranging from 19%-46%) have been attributed to reduction in total cholesterol. Low-density lipoprotein cholesterol (LDL-C) has now largely replaced total cholesterol as a risk marker and the primary treatment target for hyperlipidemia. Reduction in LDL-C levels by statin-based therapies has been demonstrated to result in a reduction in the risk of nonfatal CV events and mortality in a continuous and graded manner over a wide range of baseline risk and LDL-C levels. This article provides a review of (1) the relationship between LDL-C and CV risk from a biologic, epidemiologic, and genetic standpoint; (2) evidence-based strategies for LDL-C lowering; (3) lipid-management guidelines; (4) new strategies to further reduce CV risk through LDL-C lowering; and (5) population-level and health-system initiatives aimed at identifying, treating, and lowering lifetime LDL-C exposure.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2015.11.010

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Can lifestyle changes reverse coronary heart disease?
Ornish, D., Brown, S. E., Billings, J. H., Scherwitz, L. W., Armstrong, W. T., Ports, T. A., McLanahan, S. M., Kirkeeide, R. L., Gould, K. L., & Brand, R. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91656-u · Cited by 2,110
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Untitled work
(2012) · RePEc: Research Papers in Economics · Cited by 1,951
Cholesterol-lowering effects of dietary fiber: a meta-analysis
Brown, L., Rosner, B., Willett, W. W., & Sacks, F. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.1.30 · Cited by 1,857
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G. G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,818
Measuring the global burden of disease
Murray, C. J. L., & Lopez, A. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1201534 · Cited by 1,818
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“Niacin did not reduce the risk of major CV events and was accompanied by a range of serious adverse events.(69) The results of the much smaller AIM-HIGH trial also failed to demonstrate a CV benefit for niacin on top of statins.”
Result
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Effects of the amount and intensity of exercise on plasma lipoproteins
Kraus, W. E., Houmard, J. A., Duscha, B. D., Knetzger, K. J., Wharton, M. B., McCartney, J. S., Bales, C. W., Henes, S., Samsa, G. P., Otvos, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020194 · Cited by 1,554
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
(2015) · The Lancet · doi:10.1016/s0140-6736(14)61368-4 · Cited by 1,536
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Self-citation
Atherosclerosis is an inflammatory disease
Ross, R. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70266-8 · Cited by 1,458
The Lipid Research Clinics Coronary Primary Prevention Trial Results
(1984) · JAMA · doi:10.1001/jama.1984.03340270043026 · Cited by 1,404
Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research; Group, T. A. O. A. C. F. T. A. C. R. G. (2002) · JAMA · doi:10.1001/jama.288.23.2998 · Cited by 1,328
Long-term persistence in use of statin therapy in elderly patients
Benner, J. S. (2002) · JAMA · doi:10.1001/jama.288.4.455 · Cited by 1,232
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A. (2002) · JAMA · doi:10.1001/jama.288.4.462 · Cited by 1,077
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions
Sharrett, A. R., Ballantyne, C. M., Coady, S., HEISS, G. M., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 942
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69472-5 · Cited by 941
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis
Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
The Role of Medication Noncompliance and Adverse Drug Reactions in Hospitalizations of the Elderly
Col, N. F. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390160093019 · Cited by 765
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention A Randomized Controlled Trial
Serruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 716
Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events
Kathiresan, S., Melander, O., Anevski, D., Guiducci, C., Burtt, N. P., Roos, C., Hirschhorn, J. N., Berglund, G., Hedblad, B., Groop, L., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706728 · Cited by 696
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682
Changes in Plasma Lipids and Lipoproteins in Overweight Men during Weight Loss through Dieting as Compared with Exercise
Wood, P. D., Stefanick, M. L., Dreon, D. M., Frey-Hewitt, B., Garay, S. C., Williams, P. T., Superko, H. R., Fortmann, S. P., Albers, J. J., Vranizan, K. M., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811033191801 · Cited by 675
Health effects of trans-fatty acids: experimental and observational evidence
Mozaffarian, D., Aro, A., & Willett, W. C. (2009) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602973 · Cited by 662
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Persistence of Use of Lipid-Lowering Medications
Avorn, J., Monette, J., Lacour, A. S., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 635
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R., OLSSON, A. G., Færgeman, O., KJEKSHUS, J. K., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T. H., Þorgeirsson, G., Pyörälà, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 618
Application of New Cholesterol Guidelines to a Population-Based Sample
Pencina, M. J., Navar‐Boggan, A. M., D’Agostino, R. B., Williams, K., Neely, B., Sniderman, A. D., & Peterson, E. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315665 · Cited by 612
Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health
Fuster, V., & Kelly, B. B. (2010) · Cited by 611
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Discontinuation of Statins in Routine Care Settings: A Cohort Study
Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548
Continuous Dose-Response Relationship of the LDL-Cholesterol–Lowering Effect of Phytosterol Intake
Demonty, I., Ras, R. T., van der Knaap, H. C. M., Duchateau, G. S. M. J. E., Meijer, L., Zock, P. L., Geleijnse, J. M., & Trautwein, E. A. (2008) · Journal of Nutrition · doi:10.3945/jn.108.095125 · Cited by 516
Thirty-five-year trends in cardiovascular risk factors in Finland
Vartiainen, E. A., Laatikainen, T. K., Peltonen, M., Juolevi, A., Männistö, S., Sundvall, J., Jousilahti, P., Salomaa, V. V., Valsta, L. M., & Puska, P. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp330 · Cited by 509
Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Optimal low-density lipoprotein is 50 to 70 mg/dl
O’Keefe, J. H., Cordain, L., Harris, W. H., Moe, R. M., & Vogel, R. A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.046 · Cited by 483
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Self-citation
National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial
O’Donoghue, M. L., Braunwald, E., White, H. D., Steen, D. P., Lukas, M. A., Tarka, E., Steg, P. G., Hochman, J. S., Bode, C., Maggioni, A. P., et al. (2014) · JAMA · doi:10.1001/jama.2014.11061 · Cited by 456
Self-citation
Nut Consumption and Blood Lipid Levels: A Pooled Analysis of 25 Intervention Trials
Sabaté, J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.79 · Cited by 422 · cited 1×
“2 mg/dL and daily soy isoflavone consumption by 5 mg/dL.(50,51) Small LDL particle number has also been shown to be inversely correlated with crude-fiber consumption and positively related to dietary cholesterol intake, high-carbohydrate (and particularly high glycemic index) diets, and transfatty acid (TFA) consumpti…”
Background
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
The Myocardial Infarction Genetics Consortium Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405386 · Cited by 419
The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic
Cordain, L., Eaton, S., Brand-Miller, J. C., Mann, N. J., & Hill, K. R. (2002) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601353 · Cited by 418
Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Navar‐Boggan, A. M., Peterson, E. D., D’Agostino, R. B., Neely, B., Sniderman, A. D., & Pencina, M. J. (2015) · Circulation · doi:10.1161/circulationaha.114.012477 · Cited by 412
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
Navarese, E. P., Kołodziejczak, M. M., Schulze, V., Gurbel, P. A., Tantry, U. S., Lin, Y., Brockmeyer, M., Kandzari, D. E., Umińska, J. M., D’Agostino, R. B., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2957 · Cited by 404
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
Otvos, J. D., Mora, S., SHALAUROVA, I. Y., Greenland, P., Mackey, R. H., & Goff, D. C. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.02.001 · Cited by 385
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., & Burnett, J. R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.039 · Cited by 367
Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials
Taku, K., Umegaki, K., Sato, Y., Taki, Y., Endoh, K., & Watanabe, S. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.4.1148 · Cited by 360
Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
Cholesterol Treatment Trialists' (CTT) Collaboration (2012) · PLoS ONE · doi:10.1371/journal.pone.0029849 · Cited by 355
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Exercise training intervention after coronary angioplasty: the ETICA trial
Belardinelli, R., Paolini, I., Cianci, G., Piva, R., Georgiou, D., & Purcaro, A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01236-0 · Cited by 342
Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy
Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.064 · Cited by 340
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Interventions to improve adherence to lipid-lowering medication
van Driel, M. L., Morledge, M. D., Ulep, R., Shaffer, J. P., Davies, P., & Deichmann, R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004371.pub4 · Cited by 333
Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis
Mann, D. M., Woodward, M., Muntner, P., Falzon, L., & Kronish, I. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p150 · Cited by 329
Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005
Wijeysundera, H. C. (2010) · JAMA · doi:10.1001/jama.2010.580 · Cited by 314
Introduction to Lipids and Lipoproteins
Feingold, K. R., & Grünfeld, C. (2015) · MDText.com, Inc. eBooks · Cited by 312
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011
Ray, K. K., Kastelein, J. J. P., Boekholdt, S. M., Nicholls, S. J., Khaw, K., Ballantyne, C. M., Catapano, A. L., Reiner, E., & Lüscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu107 · Cited by 304
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics
Koren, M. J., & Hunninghake, D. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.053 · Cited by 292
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Urban, D., Pöss, J., Böhm, M., & Laufs, U. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.056 · Cited by 290
Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer
O'Keefe, J. H., & Cordain, L. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.1.101 · Cited by 289
Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002
Björck, L., Rosengren, A., Bennett, K., Lappas, G., & Capewell, S. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn554 · Cited by 264
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
Pandya, A., Sy, S., Cho, S., Weinstein, M. C., & Gaziano, T. A. (2015) · JAMA · doi:10.1001/jama.2015.6822 · Cited by 254
Effects of Physical Activity on Cardiovascular Disease
Ahmed, H. M., Blaha, M. J., Nasir, K., Rivera, J. J., & Blumenthal, R. S. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.08.042 · Cited by 253
Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.082 · Cited by 231
Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment
Stilley, C. S., Sereika, S. M., Muldoon, M. F., Ryan, C. M., & Dunbar‐Jacob, J. M. (2004) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2702_6 · Cited by 223
How do we improve patient compliance and adherence to long-term statin therapy?
Maningat, P., Gordon, B. R., & Breslow, J. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0291-7 · Cited by 208
Untangling the relationship between medication adherence and post–myocardial infarction outcomes
Choudhry, N. K., Glynn, R. J., Avorn, J., Lee, J. L.-Y., Brennan, T. A., Reisman, L., Toscano, M., Levin, R., Matlin, O. S., Antman, E. M., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.09.014 · Cited by 186
Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study
Bandosz, P., O’Flaherty, M., Drygas, W., Rutkowski, M., Koziarek, J., Wyrzykowski, B., Bennett, K., Zdrojewski, T. R., & Capewell, S. (2012) · BMJ · doi:10.1136/bmj.d8136 · Cited by 178
Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study
Linsel‐Nitschke, P., Götz, A., Erdmann, J., Brænne, I., Braund, P. S., Hengstenberg, C., Stark, K. J., Fischer, M., Schreiber, S., Mokhtari, N. E. E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002986 · Cited by 168
Twenty-Year Trends in Serum Cholesterol, Hypercholesterolemia, and Cholesterol Medication Use
Arnett, D. K., Jacobs, D. R., Luepker, R. V., BLACKBURN, H. W., Armstrong, C., & Claas, S. A. (2005) · Circulation · doi:10.1161/circulationaha.105.549857 · Cited by 166
Analysing Recent Socioeconomic Trends in Coronary Heart Disease Mortality in England, 2000–2007: A Population Modelling Study
Bajekal, M., Scholes, S., Love, H., Hawkins, N. M., O’Flaherty, M., Raine, R., & Capewell, S. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001237 · Cited by 164
Interventions to improve adherence to lipid lowering medication
Schedlbauer, A., Davies, P. A., & Fahey, T. P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004371.pub3 · Cited by 152
Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients
Kiortsis, D. N., Giral, P., Bruckert, É., & Turpin, G. (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00315.x · Cited by 133
Análisis de la disminución de la mortalidad por enfermedad coronaria en una población mediterránea: España 1988-2005
Flores‐Mateo, G., Grau, M., O’Flaherty, M., Ramos, R., Elosúa, R., Violán, C., Quesada, M., Martí‐Lluch, R., Sala, J., Marrugat, J., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.033 · Cited by 127
The problem of compliance to cholesterol altering therapy
Insull, W. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.112133000.x · Cited by 123
Factors Related to Adherence to Statin Therapy
McGinnis, B., Olson, K. L., Magid, D. J., Bayliss, E., Korner, E. J., Brand, D. W., & Steiner, J. F. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k209 · Cited by 121
Eliminating Atherogenesis in Mice by Switching Off Hepatic Lipoprotein Secretion
Lieu, H. D., Withycombe, S. K., Walker, Q. M., Rong, J. X., Walzem, R. L., Wong, J. S., Hamilton, R. L., Fisher, E. A. A., & Young, S. G. (2003) · Circulation · doi:10.1161/01.cir.0000054781.50889.0c · Cited by 118
Explaining the Decrease in Coronary Heart Disease Mortality in Italy Between 1980 and 2000
Palmieri, L., Bennett, K., Giampaoli, S., & Capewell, S. (2009) · American Journal of Public Health · doi:10.2105/ajph.2008.147173 · Cited by 116
Outpatient Electronic Health Records and the Clinical Care and Outcomes of Patients With Diabetes Mellitus
Reed, M., Huang, J., Graetz, I., Brand, R., Hsu, J., FIREMAN, B. H., & Jaffe, M. G. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-7-201210020-00004 · Cited by 116
Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100
Véniant, M. M., Sullivan, M. A., Kim, S. K., Ambroziak, P., Chu, A., Wilson, M. D., Hellerstein, M. K., Rudel, L. L., Walzem, R. L., & Young, S. G. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10695 · Cited by 114
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Catapano, A. L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Lenus, The Irish Health Repository (Dr Steevens Hospital Library) · Cited by 114
Analyzing the Coronary Heart Disease Mortality Decline in a Mediterranean Population: Spain 1988-2005
Flores‐Mateo, G., Grau, M., O’Flaherty, M., Ramos, R., Elosúa, R., Violán, C., Quesada, M., Martí‐Lluch, R., Sala, J., Marrugat, J., et al. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.05.035 · Cited by 112
Beyond Medication Prescription as Performance Measures
Arnold, S. V., Spertus, J. A., Masoudi, F. A., Daugherty, S. L., Maddox, T. M., Li, Y., Dodson, J. A., & Chan, P. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.102 · Cited by 112
Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
Steinberg, D. H., & Witztum, J. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904560106 · Cited by 106
Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 2006
Aspelund, T., Gudnason, V., Magnusdottir, B. T., Andersen, K., Sigurdsson, G., Thorsson, B., Steingrimsdottir, L., Critchley, J., Bennett, K., O'Flaherty, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013957 · Cited by 106
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D. H., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 102
The effects of prescription drug copayments on statin adherence.
Gibson, T. B., Mark, T. L., McGuigan, K. A., Axelsen, K. J., & Wang, S. S. (2006) · PubMed · Cited by 99
Influence of dietary carbohydrate and fat on LDL and HDL particle distributions
Siri, P. W., & Krauss, R. M. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0062-9 · Cited by 98
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)
Vinall, M., & Collins, R. (2009) · MD Conference Express · doi:10.1177/155989770900800804 · Cited by 97
Long-term changes in exercise capacity, quality of life, body anthropometry, and lipid profiles after a cardiac rehabilitation program in obese patients with coronary heart disease
Yu, C.-M., Li, L. S.-W., Ho, H. H., & Lau, C.-P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03159-4 · Cited by 96
Targeting Preschool Children to Promote Cardiovascular Health: Cluster Randomized Trial
Céspedes, J., Briceño, G., Farkouh, M. E., Vedanthan, R., Baxter, J., Leal, M., Boffetta, P., Woodward, M., Hunn, M., Dennis, R., et al. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.045 · Cited by 83
Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population
Kopjar, B., Sales, A. E., Piñeros, S. L., Sun, H., Li, Y.-F., & Hedeen, A. N. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.07.008 · Cited by 82
Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome
Richard, C., Couture, P., Desroches, S., Benjannet, S., Seidah, N. G., Lichtenstein, A. H., & Lamarche, B. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511003436 · Cited by 78
Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients
Maningat, P. D., & Breslow, J. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1112023 · Cited by 74
Unique character and metabolism of high density lipoprotein (HDL) in fetus
Nagasaka, H., Chiba, H., Kikuta, H., Akita, H., Takahashi, Y., Yanai, H., Hui, S.-P., Fuda, H., Fujiwara, H., & Kobayashi, K. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00663-3 · Cited by 72
Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data
Hotchkiss, J. W., Davies, C., Dundas, R., Hawkins, N. M., Jhund, P. S., Scholes, S., Bajekal, M., O’Flaherty, M., Critchley, J., Leyland, A. H., et al. (2014) · BMJ · doi:10.1136/bmj.g1088 · Cited by 71
Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men.
Williams, P. T., Krauss, R. M., VRANIZAN, K. M., Albers, J. J., Terry, R. B., & Wood, P. D. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.5.623 · Cited by 71
Patterns of Statin Initiation, Intensification, and Maximization Among Patients Hospitalized With an Acute Myocardial Infarction
Arnold, S. V., Kosiborod, M., Tang, F., Zhao, Z., Maddox, T. M., McCollam, P. L., Birt, J. A., & Spertus, J. A. (2014) · Circulation · doi:10.1161/circulationaha.113.003589 · Cited by 70
Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective
Mohammadpour, A. H., & Akhlaghi, F. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0071-8 · Cited by 70
A comparison of the effects of strength and aerobic exercise training on exercise capacity and lipids after coronary artery bypass surgery
Wosornu, D., Bedford, D., & Ballantyne, D. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014966 · Cited by 65
From Framingham to North Karelia
Puska, P. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.01.003 · Cited by 64
The ABCG5/8 Cholesterol Transporter and Myocardial Infarction Versus Gallstone Disease
Stender, S., Frikke‐Schmidt, R., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.12.055 · Cited by 64
Telemedicine diabetes consultations are cost-effective, and effects on essential diabetes treatment parameters are similar to conventional treatment: 7-year results from the Svendborg Telemedicine Diabetes project
Levin, K., Madsen, J. R., Petersen, I., Wanscher, C. E., & Hangaard, J. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700302 · Cited by 63
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
Joseph, L., & Robinson, J. G. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.04.004 · Cited by 59
Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).
Everett, B., Mora, S., Glynn, R., Macfadyen, J. G., & Ridker, P. (2014) · American Journal of Cardiology · doi:10.1016/j.amjcard.2014.08.041 · Cited by 57
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG)
Javed, U., DEEDWANIA, P. C., Bhatt, D. L., Cannon, C. P., Dai, D., Hernandez, A. F., Peterson, E. D., & Fonarow, G. C. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.014 · Cited by 56
Disparities in Screening for and Awareness of High Blood Cholesterol—United States, 1999-2002
(2005) · JAMA · doi:10.1001/jama.293.15.1849 · Cited by 48
Lipids, Lipoproteins and Apolipoproteins A I A II , B, C II , C III and E in Newborns
Averna, M. R., Barbagallo, C. M., Paola, G. D., Labisi, M., Pinna, G., Marino, G., Dimita, U., & Notarbartolo, A. (2009) · Biology of the Neonate · doi:10.1159/000243407 · Cited by 47
Being Well-Informed About Statin is Associated with Continuous Adherence and Reaching Targets
Yılmaz, M. B., Pinar, M., Naharcı, M. İ., Demirkan, B., Baysan, O., Yokuşoğlu, M., Erinç, K., Tandoğan, İ., & Işık, E. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5202-5 · Cited by 44
Relationship of dietary fat, protein, cholesterol, and fiber intake to atherogenic lipoproteins in men
Williams, P., Krauss, R. M., Kindel-Joyce, S., Dreon, D. M., VRANIZAN, K. M., & Wood, P. D. (1986) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/44.6.788 · Cited by 42
Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men
Halle, M., Berg, A., König, D., Keul, J., & Baumstark, M. W. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90300-0 · Cited by 41
Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials
Aspry, K. E., Furman, R., Karalis, D. G., Jacobson, T. A., Zhang, A. M., Liptak, G. S., & Cohen, J. D. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.004 · Cited by 41
Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
Muntner, P., Mann, D., Wildman, R. P., Shimbo, D., Fuster, V., & Woodward, M. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.019 · Cited by 38
Modelling coronary heart disease mortality in Northern Ireland between 1987 and 2007: broader lessons for prevention
Hughes, J., Kee, F., O’Flaherty, M., Critchley, J., Cupples, M., Capewell, S., & Bennett, K. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312441725 · Cited by 36
PCSK9 inhibition in patients with hypercholesterolemia
Desai, N. R., & Sabatine, M. S. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.01.009 · Cited by 29
Treatment of Elevated Cholesterol
Scirica, B. M., & Cannon, C. P. (2005) · Circulation · doi:10.1161/circulationaha.105.539106 · Cited by 27
Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids
Cohen, J. C. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.005 · Cited by 25
Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin
Krauss, R. M., Pinto, C. A., Liu, Y., Johnson‐Levonas, A. O., & Dansky, H. M. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.013 · Cited by 23
Patterns and Predictors of Intensive Statin Therapy Among Patients With Diabetes Mellitus After Acute Myocardial Infarction
Abdallah, M., Kosiborod, M., Tang, F., Karrowni, W., Maddox, T. M., McGuire, D. K., Spertus, J. A., & Arnold, S. V. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.12.040 · Cited by 13
ADHERENCE TO MEDITERRANEAN IS THE MOST IMPORTANT PROTECTOR AGAINST THE DEVELOPMENT OF FATAL AND NON-FATAL CARDIOVASCULAR EVENT: 10-YEAR FOLLOW-UP (2002-12) OF THE ATTICA STUDY
Georgousopoulou, E. N., Pitsavos, C., Panagiotakos, D. B., Chrysohoou, C. A., Skoumas, I., Chatzigeorgiou, M., & Stefanadis, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(15)61449-8 · Cited by 1

Sorted by citations

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
Landlinger, C., Pouwer, M. G., Juno, C., van der Hoorn, J. W. A., Pieterman, E. J., Jukema, J. W., Staffler, G., Princen, H. M. G., & Galabova, G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx260 · Cited by 240
Statin drugs to reduce breast cancer recurrence and mortality
Beckwitt, C. H., Brufsky, A., Oltvai, Z. N., & Wells, A. H. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1066-z · Cited by 197
The Effect of Low-Fat and Low-Carbohydrate Diets on Weight Loss and Lipid Levels: A Systematic Review and Meta-Analysis
Chawla, S., Tessarolo Silva, F., Amaral Medeiros, S., Mekary, R., & Radenkovic, D. (2020) · Nutrients · doi:10.3390/nu12123774 · Cited by 185
Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
Vinci, P., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Girolamo, F. G. D., & Biolo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111687 · Cited by 188
The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis
Summerhill, V. I., Grechko, A. V., Yet, S., Sobenin, I. A., & Orekhov, A. N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143561 · Cited by 167

See all 306

Authors: Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M.
Affiliations: Brigham and Women's Hospital (US)
University of Cincinnati (US)
Sanofi (United States) (US)
Corresponding author: Wadhera, Rishi K.
ORCID: Wadhera, Rishi K.
Steen, Dylan L.
Khan, Irfan
Giugliano, Robert P.
Venue: Journal of Clinical Lipidology
Publisher: Elsevier BV
Published: 2016-05
Volume: 10
Issue: 3
Pages: 472-489
ISSN: 1876-4789 (ISSN-L)
1933-2874
DOI: 10.1016/j.jacl.2015.11.010
OpenAlex: W2183544076
Cited by: 306
References: 165
Citations by year: 2026: 7 · 2025: 26 · 2024: 27 · 2023: 40 · 2022: 32 · 2021: 31 · 2020: 35 · 2019: 38 · 2018: 34 · 2017: 26 · 2016: 8
FWCI: 4.34
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Journal of clinical lipidology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: American Heart Association
Regeneron Pharmaceuticals
International Atherosclerosis Society
European Atherosclerosis Society
Daiichi-Sankyo
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: LDL cholesterol, cardiovascular disease, hyperlipidemia, statin therapy, LDL cholesterol lowering, cardiovascular risk, coronary heart disease mortality, cardiovascular risk reduction, total cholesterol
MeSH terms: Animals, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Life Style, Cholesterol, LDL, Risk, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks